Denise Myshko | Authors

Study Finds BluePrint Subtyping May Be Predictor for Pertuzumab Benefit in Early Breast Cancer

December 10, 2020

Data from the APHINITY trial suggested that patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay demonstrated a trend for greater benefit with adjuvant pertuzumab (Perjeta) therapy.